BeeVee by NeuraSim

Dr. Ramesh S Ve, Girish Somvanshi, Pradeep Walia, and Maciej Kossowski are Season 4's most internationally assembled medtech founders. Their collaboration spans India and Poland, supported by a US grant, combining Dr. Ramesh's neuroscience and clinical trial expertise, Girish and Pradeep's business and technology capabilities, and Maciej's European medical device and VR engineering knowledge. "Being featured on Shark Tank India was a defining moment in our mission to revolutionise eye care in India. Bringing the country's first AI-powered VR wearable to market is just the beginning. We are now focused on making BeeVee accessible in every home, ensuring that no child has to struggle with amblyopia due to outdated treatments," Dr. Ramesh shared post-show.

BeeVee™ is a VR headset pre-loaded with AI-powered gamified vision therapy exercises that treat amblyopia by exploiting neuroplasticity, the brain's ability to rewire neural pathways when properly stimulated. Unlike traditional eye patching (which passively blocks the stronger eye, forcing the weaker eye to work), BeeVee actively stimulates both eyes simultaneously through dichoptic therapy: presenting different visual stimuli to each eye, gradually training the brain to integrate inputs from both eyes equally. The gamification is BeeVee's most clinically significant design innovation: traditional amblyopia treatment in children has notoriously poor compliance because wearing an eye patch is uncomfortable, socially stigmatising (other children notice and comment), and boring (the child simply wears a patch and waits). BeeVee converts therapy into play: children engage in VR games where successful gameplay requires using both eyes together, making therapy feel like entertainment rather

Amount Asked: ₹1 crore Equity Offered: 8% Implied Pre-Money Valuation: ₹12.5 crore

Dr. Ramesh and the NeuraSim team walked into Season 4 Episode 28 with the most medically sophisticated VR demonstration of the season. They presented BeeVee's gamified vision therapy: children wearing VR headsets and playing games that simultaneously treat their lazy eye, converting a dreaded medical treatment into a fun activity that children ask to do rather than resist. The clinical results data impressed the Sharks: 2 to 6 times better outcomes than traditional eye patching, mild to severe recovery in 1 to 3 months, CE certification (European medical device compliance), and adoption by India's most prestigious eye hospitals including Aravind Eye Hospital (which serves millions of patients annually). The CTO's personal amblyopia story added emotional depth to the technical presentation.

Peyush Bansal was the most domain-relevant Shark. He appreciated the technology's vision therapy potential but raised concerns about the pre-revenue status and product readiness for commercial scaling. Anupam Mittal questioned the equity split with the international co-founder, seeking clarity on how the India-Poland corporate structure would work for Indian investors. Vineeta Singh acknowledged the medical innovation but could not construct an investment thesis from a pre-revenue medtech company with complex international founding dynamics. Namita Thapar appreciated the healthcare impact (Emcure's pharmaceutical alignment) but shared concerns about patent clarity and the competitive landscape if larger medtech companies entered VR vision therapy. Aman Gupta acknowledged the VR hardware innovation but could not see sufficient commercial readiness for boAt-style consumer scaling at this stage.

No Shark made a formal offer. All five exited before entering negotiation. The unanimous concern was readiness: the technology was medically validated (800 patients, hospital adoption, CE certification, clinical results), but the business was commercially premature (pre-revenue, complex international equity structure, unclear patent protection). The ₹12.5 crore valuation could not be justified by financial metrics alone, and the Sharks collectively decided that NeuraSim needed to convert clinical validation into commercial revenue before seeking equity investment.

Dr. Ramesh S Ve and the NeuraSim team left Shark Tank India Season 4 Episode 28 without any investment. All five Sharks declined, each acknowledging the medical breakthrough while questioning commercial readiness. The no-deal outcome was not a rejection of the technology (which every Shark praised) but a timing assessment: BeeVee needed to generate revenue, clarify IP protection, and simplify its corporate structure before attracting equity investment.

"Being featured on Shark Tank India was a defining moment in our mission to revolutionise eye care in India. Bringing the country's first AI-powered VR wearable to market is just the beginning. We are now focused on making BeeVee accessible in every home, ensuring that no child has to struggle with amblyopia due to outdated treatments." NeuraSim's post-Shark Tank trajectory has been remarkably productive despite the no-deal outcome. In collaboration with QWR (a fabless OEM XR hardware manufacturer), the company has officially launched BeeVee home therapy across the Indian market, converting the Sharks' "not ready" assessment into commercial readiness within months of the episode. BeeVee has been adopted by some of India's most prestigious eye hospitals: Aravind Eye Hospital (Madurai, one of the world's largest eye care facilities), Eye Foundation (Coimbatore), and Kasturba Hospital (Manipal). These institutional adoptions provide both clinical validation and a commercial pathway through hospital-based therapy programmes.